Publications by authors named "A Authier-Hall"
Article Synopsis
- The study aimed to see if adding a special substance called α-GalCer to a cancer treatment using cells boosts T cell responses in melanoma patients.
- Researchers tested this by giving two groups of patients different types of vaccines: one with α-GalCer and one without, and measured how well their body fought the disease.
- The results will show if the vaccine with α-GalCer is better at helping the patients’ immune system recognize and attack cancer cells.
Emerging SARS-CoV-2 variants pose a threat to human health worldwide. SARS-CoV-2 receptor binding domain (RBD)-based vaccines are suitable candidates for booster vaccines, eliciting a focused antibody response enriched for virus neutralizing activity. Although RBD proteins are manufactured easily, and have excellent stability and safety properties, they are poorly immunogenic compared to the full-length spike protein.
View Article and Find Full Text PDFProstate cancer is the second most common cancer in men worldwide. Despite an abundance of prostate-specific antigens, immunotherapies have yet to become a standard of care, potentially limited by T-cell dysfunction. Up to 10% of human circulating T-cells, and a significant fraction in the urogenital tract, are mucosal-associated invariant T (MAIT) cells.
View Article and Find Full Text PDFArticle Synopsis
- * They achieved this by attaching antigenic peptides to a weaker agonist called α-galactosylphytosphingosine (α-GalPhs), which helps in safely stimulating NKT cells.
- * This method not only proved effective in activating human T cells in lab settings but also showed promising anti-tumor effects in mice, suggesting a new approach for improving immunity against viruses and tumors.
An important goal of vaccination against viruses and virus-driven cancers is to elicit cytotoxic CD8 T cells specific for virus-derived peptides. CD8 T cell responses can be enhanced by engaging help from natural killer T (NKT) cells. We have produced synthetic vaccines that induce strong peptide-specific CD8 T cell responses in vivo by incorporating an NKT cell-activating glycolipid.
View Article and Find Full Text PDF